Decay characteristics of HIV-1-infected compartments during combination therapy
- PMID: 9144290
- DOI: 10.1038/387188a0
Decay characteristics of HIV-1-infected compartments during combination therapy
Abstract
Analysis of changes in viral load after initiation of treatment with potent antiretroviral agents has provided substantial insight into the dynamics of human immunodeficiency virus type 1 (HIV-1). The concentration of HIV-1 in plasma drops by approximately 99% in the first two weeks of treatment owing to the rapid elimination of free virus with a half-life (t1/2) of < or =6 hours and loss of productively infected cells with a t1/2 of 1.6 days. Here we show that with combination therapy this initial decrease is followed by a slower second-phase decay of plasma viraemia. Detailed mathematical analysis shows that the loss of long-lived infected cells (t1/2 of 1-4 weeks) is a major contributor to the second phase, whereas the activation of latently infected lymphocytes (t1/2 of 0.5-2 weeks) is only a minor source. Based on these decay characteristics, we estimate that 2.3-3.1 years of a completely inhibitory treatment would be required to eliminate HIV-1 from these compartments. To eradicate HIV-1 completely, even longer treatment may be needed because of the possible existence of undetected viral compartments or sanctuary sites.
Comment in
-
Down or out in blood and lymph?Nature. 1997 May 8;387(6629):123-4. doi: 10.1038/387123a0. Nature. 1997. PMID: 9144275 No abstract available.
Similar articles
-
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.J Infect Dis. 2000 Feb;181(2):491-7. doi: 10.1086/315244. J Infect Dis. 2000. PMID: 10669331 Clinical Trial.
-
Human immunodeficiency virus type-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells.Virology. 1997 Sep 15;236(1):104-9. doi: 10.1006/viro.1997.8718. Virology. 1997. PMID: 9299622
-
Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.Antivir Ther. 2000 Sep;5(3):215-25. Antivir Ther. 2000. PMID: 11075942 Clinical Trial.
-
Antiretroviral therapy in human immunodeficiency virus-infected individuals.Adv Intern Med. 1998;43:373-402. Adv Intern Med. 1998. PMID: 9506188 Review. No abstract available.
-
Acute human immunodeficiency virus type 1 infection.N Engl J Med. 1998 Jul 2;339(1):33-9. doi: 10.1056/NEJM199807023390107. N Engl J Med. 1998. PMID: 9647878 Review. No abstract available.
Cited by
-
Endothelial cell stimulation overcomes restriction and promotes productive and latent HIV-1 infection of resting CD4+ T cells.J Virol. 2013 Sep;87(17):9768-79. doi: 10.1128/JVI.01478-13. Epub 2013 Jul 3. J Virol. 2013. PMID: 23824795 Free PMC article.
-
Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.PLoS Pathog. 2020 Aug 25;16(8):e1008791. doi: 10.1371/journal.ppat.1008791. eCollection 2020 Aug. PLoS Pathog. 2020. PMID: 32841299 Free PMC article.
-
A novel PCR assay for quantification of HIV-1 RNA.J Virol. 2013 Jun;87(11):6521-5. doi: 10.1128/JVI.00006-13. Epub 2013 Mar 27. J Virol. 2013. PMID: 23536672 Free PMC article.
-
Molecular clock of HIV-1 envelope genes under early immune selection.Retrovirology. 2016 Jun 1;13(1):38. doi: 10.1186/s12977-016-0269-6. Retrovirology. 2016. PMID: 27246201 Free PMC article.
-
Human Immunodeficiency Virus 1 (HIV-1): Viral Latency, the Reservoir, and the Cure.Yale J Biol Med. 2020 Sep 30;93(4):549-560. eCollection 2020 Sep. Yale J Biol Med. 2020. PMID: 33005119 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical